Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,498,142
  • Shares Outstanding, K 165,221
  • Annual Sales, $ 726,440 K
  • Annual Income, $ -61,290 K
  • 60-Month Beta 0.42
  • Price/Sales 3.38
  • Price/Cash Flow N/A
  • Price/Book 5.40
Trade ACAD with:

Options Overview Details

View History
  • Implied Volatility 43.42% ( -0.74%)
  • Historical Volatility 40.06%
  • IV Percentile 27%
  • IV Rank 28.32%
  • IV High 95.33% on 02/15/24
  • IV Low 22.91% on 11/20/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 102
  • Volume Avg (30-Day) 2,798
  • Put/Call OI Ratio 1.32
  • Today's Open Interest 34,137
  • Open Int (30-Day) 33,590

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.16
  • Number of Estimates 9
  • High Estimate 0.26
  • Low Estimate 0.09
  • Prior Year 0.01
  • Growth Rate Est. (year over year) +1,500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.72 +1.49%
on 05/14/24
17.58 -15.04%
on 05/03/24
-2.14 (-12.53%)
since 04/16/24
3-Month
14.72 +1.49%
on 05/14/24
26.56 -43.75%
on 02/27/24
-10.17 (-40.50%)
since 02/16/24
52-Week
14.72 +1.49%
on 05/14/24
33.99 -56.05%
on 07/18/23
-6.94 (-31.72%)
since 05/16/23

Most Recent Stories

More News
Acadia: Q1 Earnings Snapshot

Acadia: Q1 Earnings Snapshot

ACAD : 14.86 (-1.72%)
Acadia: Q4 Earnings Snapshot

Acadia: Q4 Earnings Snapshot

ACAD : 14.86 (-1.72%)
Acadia: Q3 Earnings Snapshot

Acadia: Q3 Earnings Snapshot

ACAD : 14.86 (-1.72%)
Why Acadia Pharmaceuticals Stock Is Rising Today

An analyst upgrade is sparking a rally in the drugmaker's shares today.

JPM : 204.20 (+1.03%)
ACAD : 14.86 (-1.72%)
2 Growth Stocks I'd Buy on the Dip

These two growth stocks could be worthwhile buy-and-holds.

BUD : 66.50 (+0.71%)
ACAD : 14.86 (-1.72%)
TLRY : 2.13 (+2.90%)
2 Supercharged Growth Stocks Billionaires Can't Stop Buying

A top hedge fund has been steadily buying these two growth stocks in 2023.

PFE : 28.83 (+0.03%)
ACAD : 14.86 (-1.72%)
ROIV : 11.40 (-0.87%)
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 45.27 (-1.20%)
KNSA : 20.16 (+0.30%)
ACAD : 14.86 (-1.72%)
HRMY : 29.39 (-1.04%)
AMPH : 41.85 (-1.39%)
INCY : 56.67 (-0.67%)
AGEN : 10.51 (-2.50%)
NVS : 102.51 (-0.69%)
PFE : 28.83 (+0.03%)
SGEN : 228.74 (-0.07%)
MRK : 131.07 (-0.50%)
RXDX : 199.92 (+0.09%)
Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?

This biotech stock has been on fire in 2023.

ACAD : 14.86 (-1.72%)
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street

This small-cap biotech might be a hidden gem.

ACAD : 14.86 (-1.72%)
STOK : 14.15 (+0.14%)
Acadia: Q2 Earnings Snapshot

Acadia: Q2 Earnings Snapshot

ACAD : 14.86 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 15.71
2nd Resistance Point 15.53
1st Resistance Point 15.33
Last Price 14.86
1st Support Level 14.95
2nd Support Level 14.77
3rd Support Level 14.57

See More

52-Week High 33.99
Fibonacci 61.8% 26.63
Fibonacci 50% 24.36
Fibonacci 38.2% 22.08
Last Price 14.86
52-Week Low 14.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar